T. Rowe Price Associates’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $401K | Buy |
35,697
+5,150
| +17% | +$57.9K | ﹤0.01% | 2404 |
|
|
2025
Q1 | $140K | Buy |
30,547
+1,549
| +5% | +$7.1K | ﹤0.01% | 2753 |
|
|
2024
Q4 | $164K | Sell |
28,998
-11,116
| -28% | -$62.9K | ﹤0.01% | 2739 |
|
|
2024
Q3 | $195K | Buy |
40,114
+10,800
| +37% | +$52.5K | ﹤0.01% | 2660 |
|
|
2024
Q2 | $144K | Buy |
29,314
+3,948
| +16% | +$19.4K | ﹤0.01% | 2675 |
|
|
2024
Q1 | $337K | Buy |
25,366
+5,600
| +28% | +$74.4K | ﹤0.01% | 2382 |
|
|
2023
Q4 | $276K | Buy |
19,766
+1,446
| +8% | +$20.2K | ﹤0.01% | 2419 |
|
|
2023
Q3 | $243K | Buy |
18,320
+1,447
| +9% | +$19.2K | ﹤0.01% | 2424 |
|
|
2023
Q2 | $317K | Buy |
16,873
+1,440
| +9% | +$27.1K | ﹤0.01% | 2333 |
|
|
2023
Q1 | $223K | Buy |
15,433
+628
| +4% | +$9.07K | ﹤0.01% | 2471 |
|
|
2022
Q4 | $286K | Sell |
14,805
-450
| -3% | -$8.69K | ﹤0.01% | 2386 |
|
|
2022
Q3 | $525K | Buy |
+15,255
| New | +$525K | ﹤0.01% | 2092 |
|
|
2022
Q1 | – | Sell |
-5,969
| Closed | -$220K | – | 3011 |
|
|
2021
Q4 | $220K | Buy |
+5,969
| New | +$220K | ﹤0.01% | 2718 |
|
|
2021
Q3 | – | Sell |
-685,000
| Closed | -$41.3M | – | 2977 |
|
|
2021
Q2 | $41.3M | Buy |
+685,000
| New | +$41.3M | ﹤0.01% | 1098 |
|